News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Jeanne Linke Northrop

Advertisement

Articles by Jeanne Linke Northrop

Dave Bearss, PhD, CEO, Halia Therapeutics Image courtesy of Halia Therapeutics

Pushing Boundaries to Revolutionize Chronic Inflammation Therapy

ByJeanne Linke Northrop
June 13th 2024

Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.

Advertisement

Latest Updated Articles

  • Dave Bearss, PhD, CEO, Halia Therapeutics Image courtesy of Halia Therapeutics
    Pushing Boundaries to Revolutionize Chronic Inflammation Therapy

    June 13th 2024



Advertisement
Advertisement

Trending on PharmExec

1

FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents

2

Pharma Funding Roundup: Excalipoint Therapeutics Completes $68.7 Million Seed Finance Round, Crossbow Therapeutics Raises $77 Million in Series B Financing

3

Conflict in Middle East Disrupts Pharma Drug Supplies: Report

4

What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them

5

How is eClinical Positioning its Platform Capabilities to Help Sponsors?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us